J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2466KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 92(9): 1241-1245, 1991

Report on the annual meeting

IMMUNE RESPONSE IN CANCER PATIENTS TREATED WITH ADJUVANT IMMUNOCHEMOTHERAPY

1) The First Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Japan
2) The First Department of Surgery, Okayama University School of Medicine, Okayama, Japan

Matsuro Fukushima1), Akira Gochi2), Hisaaki Koie1), Kunzo Orita2)

In order to evaluate the immune response in cancer patients treated with adjuvant immunochemotherapy, a committee was organized in Japanese research Socity for Surgical Cancer lmmunology. Skin reactions, subsets of PBL, HLA, immunosuppressor (IAP), Immunoactivity (NK activity and lymphoblastogenesis with PHA), general nutritional condition and performance status were picked up and discussed as to how these reactions influence the prognosis of patients.
For example, 395 cases of gastric cancer (excluded stage I, non-chemotherapy and absolute non-curative resection) collected from the committee's hospital were divided into two groups, according to a statistical “cut off point”, i.e., more than 5.9g/dl of TP, 4.0g/dl of Alb, and 1500/mm3 of PBL, and values less than these. The five-year survival rate was significantly high in the former group. In the group that kept high counts of these parameters after operation, the 5-year survival rate was significantly high in cases which received immunotherapy.
In conclusion, immunoparameters paralleled to the stage of disease and prognosis. When the parameters remained at high levels after operation, the immunotherapy group showed good survival compared to the nonimmunotherapy group. Immunotherapy is not valuable in patients with high LAP levels and poor nutritional condition.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.